These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20492887)

  • 41. Etanercept.
    Ducharme E; Weinberg JM
    Expert Opin Biol Ther; 2008 Apr; 8(4):491-502. PubMed ID: 18352852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spontaneous resolution of lupus nephritis following withdrawal of etanercept.
    Yahya TM; Dhanyamraju S; Harrington TM; Prichard JW
    Ann Clin Lab Sci; 2013; 43(4):447-9. PubMed ID: 24247804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of psoriasis with anti-TNF drugs in human immunodeficiency virus-infected patients].
    de Unamuno-Bustos B; Ballester-Sánchez R; Pérez-Ferriols A; Sánchez Carazo JL
    Med Clin (Barc); 2012 May; 138(13):593-4. PubMed ID: 22036464
    [No Abstract]   [Full Text] [Related]  

  • 45. Etanercept: efficacy and safety for approved indications.
    Kerensky TA; Gottlieb AB; Yaniv S; Au SC
    Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
    Cecchi R; Bartoli L
    Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Long term efficacy and safety of etanercept in psoriasis].
    García-Patos Briones V; Mollet Sánchez J
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():12-7. PubMed ID: 20492875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Etanercept and infections].
    Ribera M; Leal L; Luelmo J
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():70-6. PubMed ID: 20492884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature.
    Mourão AF; Rustin M; Isenberg D
    Clin Exp Rheumatol; 2010; 28(3):408-10. PubMed ID: 20576227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.
    Esposito M; Giunta A; Mazzotta A; Babino G; Talamonti M; Chimenti MS; Chimenti S
    Int J Immunopathol Pharmacol; 2010; 23(2):503-9. PubMed ID: 20646345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
    Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
    Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etanercept therapy for psoriasis in a patient with numerous comorbidities.
    De Simone C; Carbone A; Caldarola G
    Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recall injection-site reactions to etanercept in a patient with psoriasis.
    Papadavid E; Makris M; Dalamaga M; Kalogeromitros D; Stavrianeas N
    Clin Exp Dermatol; 2009 Apr; 34(3):414-5. PubMed ID: 19120391
    [No Abstract]   [Full Text] [Related]  

  • 59. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
    Stone JH; Holbrook JT; Marriott MA; Tibbs AK; Sejismundo LP; Min YI; Specks U; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune WJ; Ytterberg SR; Allen NB; Hoffman GS;
    Arthritis Rheum; 2006 May; 54(5):1608-18. PubMed ID: 16646004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Etanercept in childhood psoriasis].
    Pérez-Barrio S; Careaga JM
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():50-4. PubMed ID: 20492881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.